2016 American Transplant Congress
Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.
Washington University School of Medicine, Saint Louis, MO.
Background: While CMV prevention strategies have been studied in carefully selected groups of patients enrolled in randomized trials, their comparative effectiveness in real-world settings is…2016 American Transplant Congress
CMV Monitoring Reduces Risk of Clinical Complications in Kidney Transplant Recipients.
MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC.
Objective: Review the advantages of CMV viral load monitoring in preventing CMV associated complications in kidney transplant recipientsMethods: All individuals who underwent a kidney transplant…2016 American Transplant Congress
Late-Onset Pneumocystis Jirovecii Pneumonia After Renal Transplantation: A Case-Control Study.
BackgroundPneumocystis jirovecii pneumonia (PCP) usually occurs during the first year after solid organ transplantation. Introduction of routine prophylaxis have reduced the incidence of PCP drastically.…2016 American Transplant Congress
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Background: Studies suggest low-level cytomegalovirus (CMV) viraemia, detected with sensitive molecular assays, may lead to poorer graft outcomes following renal transplantation.Aims: Investigate the incidence, outcomes,…2016 American Transplant Congress
Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?
Kidney Transplantation Service, Hospital das Clinicas - University of Sao Paulo, Sao Paulo, Brazil.
Thymoglobulin (ATG) used as induction therapy is considered a risk factor for CMV disease in renal transplantation (RTx) and prophylaxis is recommended. Our center policy…2016 American Transplant Congress
Give One and Done? Evaluating a Change in Surgical Prophylaxis in Kidney Transplant Recipients.
Pharmacy, University of Utah Hospital and Clinics, Salt Lake City, UT.
Surgical-site infections (SSIs) occur in up to 11% of kidney transplant (txp) patients (pts). There is no consensus on the optimal peri-op prophylaxis regimen for…2016 American Transplant Congress
Impact of Morbid Obesity on Breakthrough CMV Infection in Kidney Transplant Recipients.
Medical University of South Carolina, Charleston, SC.
Purpose: The aim of this study was to assess the impact of obesity on risk for cytomegalovirus (CMV) infection after kidney transplantation as well as…2016 American Transplant Congress
Outcomes of Anticoagulation Use for Portal Vein Thrombosis in University of Wisconsin Liver Transplant Patients.
Background: The prevalence of Portal Vein Thrombosis (PVT) in cirrhotic liver transplant patients increases the risk of morbidity and mortality post-liver transplantation. Current research suggests…2016 American Transplant Congress
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
1IU Health, University Hospital, Indianapolis, IN; 2Butler University, Indianapolis, IN.
Valganciclovir is the preferred prophylactic therapy for the prevention of CMV in transplant recipients and is the most expensive medication required post transplantation. The objective…2015 American Transplant Congress
Deep Surgical Site Infections (dSSI) After Liver Transplantation (LTx): Emergence of Multiple-Drug Resistant (MDR) Pathogens
Purpose: We described the epidemiology, microbiology and outcomes of dSSI after LTx.Methods: We performed a single center retrospective study of 332 consecutive patients undergoing LTX…
American Transplant Congress abstracts